CJC-1295 No DAC & Ipamorelin: Intermediate Strategies

At the intermediate stage, strategy around CJC-1295 no DAC and ipamorelin stops being about the molecules and starts being about the paperwork behind them. Research characterises the two as acting on separate upstream receptors, which is why laboratories request them in the same order — but for a business buying at volume, the decision that actually moves the needle is whether every lot on your shelf carries a batch-specific certificate of analysis you can read before you pay. Real Peptides supplies both compounds strictly for research use and publishes verifiable COAs. It does not publish protocols, dosing, or preparation guidance of any kind, and no responsible wholesale supplier should.

Why these two compounds sit next to each other in a catalogue

CJC-1295 no DAC appears in much of the literature under a second name, modified GRF (1-29). It is a growth hormone releasing hormone analogue — a shortened, substituted version of the native GHRH sequence engineered to resist enzymatic breakdown. Ipamorelin is a pentapeptide that studies describe as a selective agonist at the growth hormone secretagogue receptor, the receptor family associated with ghrelin signalling. Because the two engage different upstream targets, investigators studying signalling interaction tend to want both on the bench at once. That is the entire reason they co-occur in order histories.

The DAC distinction is where purchase orders go wrong most often. DAC refers to a drug affinity complex, a moiety that binds serum albumin and substantially extends how long the molecule persists in circulation. The no-DAC version omits it. Two products with nearly identical names therefore behave very differently in a study design, and ordering the wrong one is not a variant issue — it is the wrong molecule. When you build SKU codes, reorder templates, or storefront listings, DAC status belongs in the product name itself, never in a footnote or a parenthetical the picker can miss.

None of that is use guidance. It is sequence and structure information a buyer needs in order to stock the right item and describe it accurately to research customers.

Reading the pair side by side

The table is a sourcing aid, not a comparison of effects. Both are research-use-only compounds, and neither is an approved drug for any human application.

What actually changes after your first few orders

A first order is a test. You are checking whether vials arrive intact, whether the label matches the invoice, whether a certificate exists at all. The intermediate phase is structurally different, because you are now making commitments — to a reorder cadence, to shelf space, to customers who expect the same item to be there next month. Three variables that were irrelevant on order one become decisive.

Lot consistency. A supplier can pass one test and still drift between production runs. The intermediate buyer stops reading a single COA in isolation and starts comparing certificates across lots, looking for whether purity, identity and impurity profile hold steady over time. A supplier who cannot produce prior lot documentation on request is asking you to take consistency on faith.

Catalogue logic. Demand for one GHRH-analogue or secretagogue item rarely stays isolated. Buyers who stock this pair generally find their research customers asking about adjacent categories, and depth within one research area is easier to support operationally than a thin scatter across a dozen unrelated ones. Depth also improves your leverage on tiered pricing, because your volume concentrates rather than fragments.

Forecasting. Lead time only becomes a business variable once you reorder on a schedule. At that point, a published and predictable fulfilment window beats a marginally lower headline price from a supplier who cannot tell you when the next batch ships. Stockouts cost more than unit cost differences, and they cost trust, which does not reappear on the next invoice.

The documentation that should travel with every lot

Ask for the certificate before the order, not after. A COA that appears only once payment clears is a marketing document, not a quality record. Specific things to look for:

Lot-level linkage. The certificate should reference the exact lot number printed on the vial you received. A generic product-level certificate tells you what a good batch once looked like, not what is in your hand.

Purity by HPLC. High-performance liquid chromatography is the standard method for quantifying peptide purity. Look for the chromatogram itself where available, not just a summary number typed onto a letterhead.

Identity confirmation. Purity tells you how much of the vial is one substance. Mass spectrometry tells you whether that substance is the sequence you ordered. A high purity figure without identity confirmation is an incomplete claim, and for a longer substituted sequence like modified GRF (1-29), identity is the analysis that catches substitution errors.

Net peptide content. Synthesised peptides are typically isolated as salts, and the counterion contributes mass. Gross vial weight and net peptide content are not the same figure. Reputable documentation distinguishes the two; documentation that never mentions the distinction is worth a follow-up question.

Contamination panels. Sterility, endotoxin, heavy metals, residual solvents and water content are the analyses serious buyers expect to see addressed. Real Peptides runs 7-panel batch testing on its lots and makes the results publicly viewable rather than gating them behind a sales conversation.

Independence. Ask who performed the testing and whether raw reports are available. In-house-only data is not disqualifying on its own, but it should be disclosed plainly rather than implied to be third-party.

Program mechanics worth interrogating before you commit

Wholesale terms vary enormously across this industry, and the differences that matter are rarely the ones advertised. Work through these before signing anything.

Is pricing published or quote-only? Quote-only pricing is not automatically a problem, but it makes margin modelling guesswork and it makes price consistency across your own customer base harder to defend. Are minimums set per SKU or per order? A per-SKU minimum forces you to deepen inventory in items you have not yet validated with demand; a per-order minimum lets you spread a first commitment across several compounds while you learn what sells.

Do certificates cost extra? Some operations treat testing documentation as a paid add-on or a per-request favour. Documentation you have to purchase separately is documentation some of your competitors will skip, which is exactly how unverified material reaches the market. Ask what happens when a shipment arrives damaged, what the reship policy is, and whether cold-chain or protective packaging is standard or upsold. Ask whether white-label or private-label support exists if you plan to build a brand, and what the lead time looks like on labelled versus stock inventory.

Finally, ask what the supplier will not do. A supplier who offers to advise on protocols, preparation, or end use is telling you something about their compliance posture, and it is not flattering. The correct answer from a research-use-only wholesaler is that they supply and document the compound, and nothing beyond that.

Questions that belong with your attorney, not your supplier

This section is informational and is not legal advice. Research-use-only labelling is a statement about the intended market for the material, and what your specific business entity may lawfully purchase, hold, label, or resell depends on your structure, your licences, and the jurisdiction you operate in. Those questions are not settled by anything a supplier's website says.

Bring a defined list to your counsel rather than a general enquiry. What is our entity permitted to purchase and resell under our current licensure? What labelling and record-keeping obligations attach to material we hold for resale? Does reselling under our own brand change our position relative to buying and reselling in the original packaging? What questions should we put to our state board before we list these items, and what documentation should we retain per lot and for how long? How should our own marketing language be constrained so that nothing we publish reframes a research compound as something else?

No supplier can answer those for you, and any who claim to should be treated with suspicion. Your compliance obligations are yours, and they generally do not transfer with a shipment.

What Real Peptides does differently

Real Peptides operates the Wholesale Partner Program on a straightforward premise: the buyer should be able to verify the product before committing, not after.

Compounds are produced to 99%+ HPLC purity, and each batch goes through 7-panel testing rather than a single purity check. Certificates of analysis are publicly verifiable — a prospective partner can read the lab results for a lot directly, without a sales call, an account, or a separate fee. That is a deliberate contrast with a common industry pattern in which testing is described in general terms, certificates are provided only on request, and purity claims cannot be independently checked at all.

Fulfilment runs from the United States, with orders shipping within a 5–7 day window, which makes reorder cadence something you can plan around instead of guess at. The wholesale application itself is a 3-step process, designed so that a qualified business can be evaluated and onboarded without a drawn-out negotiation. Both CJC-1295 No DAC 10mg and Ipamorelin 10mg are catalogue items with their own batch documentation, and everything in the catalogue is supplied for laboratory research use only.

If your research customers are working in this area, adjacent items in the Growth Factor & Tissue Signaling Research collection — including Tesamorelin 10mg and, on the tissue side, BPC-157 10mg and TB-500 10mg — tend to be the next line items buyers deepen into, and the same batch-testing and COA standards apply across the Popular Peptides range.

If you are past the trial-order stage and ready to buy on a schedule, the next move is the Wholesale Partner Program application. Read the published certificates for the lots you would be stocking first, compare them against whatever your current supplier will show you, and bring your licensing questions to your own counsel before you list anything. A supplier relationship worth building is one that survives that level of scrutiny.